Yahoo Finance

Market Cap: A$211.59M

Cettire Limited, with a market cap of A$211.59 million, has seen its weekly volatility decrease from 19% to 12% over the past year, indicating reduced returns volatility. Despite no debt and short-term assets covering liabilities, Cettire's profit margins dropped to 0.3% from 3.6% last year due to large one-off gains impacting results. The board's recent changes include appointing Steven Fisher as Chair and Daniel Agostinelli as an Independent Director, both bringing extensive retail experience which may support strategic growth efforts amidst challenges like negative earnings growth of -88.4%. The stock trades at a significant discount below estimated fair value.

• Dive into the specifics of Cettire here with our thorough balance sheet health report.

• Examine Cettire's earnings growth report to understand how analysts expect it to perform.

PolyNovo

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally with a market cap of A$1.15 billion.

Operations: PolyNovo generates revenue of A$115.58 million from the development, manufacturing, and commercialization of its NovoSorb technology.

Market Cap: A$1.15B

PolyNovo Limited, with a market cap of A$1.15 billion, has demonstrated significant growth, reporting a 31.1% increase in revenue to A$91.6 million for the year-to-date ending March 2025. The company's earnings have accelerated considerably, growing by 270.2% over the past year and surpassing its five-year average growth rate of 46.5%. Despite an inexperienced management team with an average tenure of 1.3 years, PolyNovo's financial health remains robust with more cash than total debt and short-term assets exceeding liabilities. However, negative operating cash flow indicates potential challenges in covering debt obligations fully through cash generation alone.

• Unlock comprehensive insights into our analysis of PolyNovo stock in this financial health report.

• Review our growth performance report to gain insights into PolyNovo's future.

Make It Happen

• Reveal the 994 hidden gems among our ASX Penny Stocks screener with a single click here.

• Contemplating Other Strategies? AI is about to change healthcare. These 23 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:BOE ASX:CTT and ASX:PNV.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com